Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.
Cut off from the world in his solitary confinement in the Jodhpur jail, climate activist Sonam Wangchuk has turned his attention to a group of usually unremarkable visitors -- ants. Perhaps, he is drawn to the sense of solidarity and team spirit they display, his wife and HIAL co-founder Gitanjali Angmo says.
A water contamination outbreak in Indore has led to multiple deaths and illnesses. Health officials are conducting surveys and providing aid to affected residents.
Home Minister Amit Shah criticized the opposition in Rajya Sabha, linking the division of the 'Vande Mataram' song to the partition of India. He accused Congress and Jawaharlal Nehru of dividing the song for appeasement politics.
November 7 2025, marked the 150th year of India's revered national song, Vande Mataram.
The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Jyotindranath Mukherjee, popularly known as Bagha Jatin, attained martyrdom while fighting the British in Balasore district on September 9, 1915. It is unfortunate that the supreme sacrifice made by Bagha Jatin and his associates is little known outside Bengal and Odisha.
US accounts for a large part of revenue for top Indian pharma companies like Gland Pharma (54 percent), Dr Reddy's (53 per cent), and Aurobindo Pharma (48 per cent).
It will be too premature to draw conclusions on the role of pilots from the preliminary investigation report into the fatal crash of Air India plane last month and the final report will mention about the most probable cause for the accident, former Aircraft Accident Investigation Bureau (AAIB) chief Aurobindo Handa said on Sunday.
Air India's CEO defends the fitness of pilots and aircraft after a preliminary report into the crash of flight AI171 raised questions. He urged against premature conclusions as the investigation continues.
'Who tried engine relight?' 'If the first officer was the one flying at takeoff, the captain may have taken control immediately post-thrust loss.' 'But the AAIB report doesn't clarify any of this.'
Movement in the equity market this week will be guided by a host of macroeconomic data announcements, global trends and trading activity of foreign investors, analysts said. Stocks markets concluded the last week on a subdued note, as investors grappled with global uncertainties.
Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains coming in the last three months. The stock is riding on multiple triggers given its investments in the production-linked incentive or PLI scheme, biosimilars, injectables and vaccines, which should drive revenues and profits over the medium term. Better than expected performance after the June quarter results led to a revision of earnings estimates for FY24 and FY25.
One can only sincerely wish the Dalai Lama a very long life at the service of world peace. His presence is much required today on the planet, notes Claude Arpi, who has known His Holiness for more than half a century.
Bill Aitken came to India nearly 60 years ago. He never returned. An Indian citizen since 1972, he tells Rediff.com's Archana Masih how India changed his life forever.
Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.
The Uttar Pradesh government has said that over 65 crore people visited the sacred site in Prayagraj since the Maha Kumbh began on January 13.
V Vijayasai Reddy, a Rajya Sabha member from the YSRCP, has announced his decision to quit politics and resign from his parliamentary membership. He stated that agriculture will be his future and that his decision was personal, with no pressure or influence from others. Reddy's announcement comes as the YSRCP faces challenges after its defeat in the 2024 Assembly elections. He thanked YSRCP supremo YS Jagan Mohan Reddy for providing him the Rajya Sabha opportunity and highlighted his working relationship with the ruling TDP and Deputy Chief Minister Pawan Kalyan.
'We were asked to add a dialogue where the politician says she admires Mrs Gandhi.'
Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.
Around 40 schools in Delhi received a bomb threat mail Monday morning with the sender demanding US
Company had earlier received an import alert in February this year from the US Food and Drug Administration.
USFDA issues Form 483 with as many as 14 observations that could impact ongoing operations at Aurobindo's Pashamailaram facility in Hyderabad.
The focus of the company would be to develop its capability across segments of injectables, vaccines, biosimilars, inhalation and APIs to drive growth.
In its first acquisition in Europe, Aurobindo Pharma Ltd today said it has acquired UK-based Milpharm Ltd, in an all cash deal, from Whyte Group and Iracot Ltd.
The company has received the tentative approval from the US Food & Drug Administration to manufacture and market these combination tablets in strengths of 600mg/300mg/ 300mg, a statement by Aurobindo Pharma said.
The tailwind of low price erosion in the US generics market, seen by domestic pharmaceutical companies in calendar year 2023 (CY23), may be reversing slowly, caution analysts. According to the latest data from US-based Centers for Medicare and Medicaid Services (CMMS), price erosion in calendar year 2024 (CY24) on a year-to-date (YTD) basis stood at a high of 15 per cent in the oral solid dosage (OSD) segment compared to a low of 1 per cent in CY23. This erosion, according to a report by Antique Stock Broking, was the highest in the last three years.
Hyderabad-based bulk drug major Aurobindo Pharma is looking at acquiring a $100 million European company to launch its operations in the continent.
The two leaders had a complex relationship yet formed a partnership and even after their parting of ways, the two admired each other in their efforts for India's freedom.
The city's 24-hour Air Quality Index (AQI), recorded at 4 pm daily, stood at 417, making it the worst in the country. On Friday, the AQI level was 396.
Pfizer Inc and its group companies filed a petition in a US court against Aurobindo Pharma Ltd and Dr Reddy's Laboratories alleging that the Indian drug-makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent.
Import alert on unit-6 facility might be lifted by FDA by Sept.
Aurobindo Pharma has received licences from Bristol Myers Squibb Co to market two anti-AIDS drugs in 49 countries.
Aurobindo Pharma has acquired business assets of the UK-based generic drug maker Milpharm.
According to the petition copies, Hospira has alleged that Aurobindo's Abbreviated New Drug Application (ANDA) to make generic version of dexmedetomidine hydrochloride injection would infringe its patented drug Precedex.
Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and amortisation) margins are anticipated to improve by about 110 basis points. Ebitda improvement will be led by lower input costs because prices of active pharmaceutical ingredients (APIs) are 5-15 per cent lower year-on-year (Y-o-Y). Axis Capital said sales growth would be around 10 per cent, of which growth in the India market would be 11 per cent or so.
Both the units were under the scanner of FDA since 2011.
The Centre and Orissa Government on Thursday informed the Orissa High Court that they would take immediate steps to ban publication and circulation of controversial book titled The Life of Sri Aurobindo written by US writer Peter Hasse.
Here is the Brahma Mantra for mankind. So long as the world has leaders with judgement -- humane, compassionate, and no-nonsense in their thinking -- natural intelligence will prevail, notes R Gopalakrishnan.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances